Tanzania Infectious Disease Therapeutics Market Report 2022 to 2030

Tanzania Infectious Disease Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Tanzania infectious disease therapeutics market will reach a value of $72.2 Mn from $47.9 Mn in 2022, growing at a CAGR of 5.3% during 2022-2030. The Infectious Disease Therapeutics in Tanzania is dominated by a few domestic pharmaceutical companies such as Tanzania Pharmaceutical Industries, Keko Pharmaceutical and Zenufa Laboratories. The Infectious Disease Therapeutics market in Tanzania is segmented into different therapeutic areas and different diseases type. The major factors affecting the Tanzania infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of Tanzania.

ID: IN10TZPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Vishwa Modhia

Buy Now

Tanzania Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Tanzania infectious disease therapeutics market will reach a value of $72.2 Mn from $47.9 Mn in 2022, growing at a CAGR of 5.3% during 2022-2030.

Tanzania is a low-income, developing country in East Africa bordering the Indian Ocean. Tanzania is particularly vulnerable to the infectious diseases listed below, according to the World Factbook. Bacterial and protozoal diarrhoea, hepatitis A, and typhoid fever are all examples of food or waterborne illnesses. In Tanzania, water-borne infectious illnesses such as schistosomiasis are frequent. Tanzania's major infectious diseases are rabies, malaria, dengue fever, and Rift Valley fever.

Tanzania has the second greatest number of cases of schistosomiasis in Sub-Saharan Africa, after only Nigeria. Malaria is the major cause of morbidity and mortality in Tanzania, affecting an estimated 93 % of the population. Tanzania's government spends 3.8% of its GDP on healthcare.

Tanzania Infectious Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Tanzania has a substantial tuberculosis problem, with an estimated 70,000 new cases recorded each year. Another important health concern in Tanzania is HIV/AIDS, which is predicted to affect 1.4 Mn people by 2020. In Tanzania, the prevalence rate was 19% in 1977, but by 2012, it has risen to 51.5 % (more than 23 Mn people). In 2019, over 15 Mn Tanzanians required schistosomiasis therapy. To combat the spread of malaria, the government has launched a variety of measures, including the distribution of insecticide-treated bed nets, indoor residual spraying, and the distribution of antimalarial medications. These aspects could boost Tanzania's infectious disease therapeutics market.

Market Restraints

Schistosomiasis is classified as a "disease of poverty" by the World Health Organization (WHO). Schistosomiasis is classified as a neglected tropical disease (NTD) because it mostly affects tropical areas "where people do not have access to safe means to dispose of human waste." Tanzania's health infrastructure is deplorable, with few resources for disease surveillance, prevention, and control. This can make it difficult to deliver infectious illness therapies effectively and limit the market potential for innovative treatments. These factors may deter new entrants into the Tanzania infectious disease therapeutics market.

Competitive Landscape

Key Players

Tanzania Pharmaceutical Industries (TPI): TPI is a state-owned pharmaceutical company based in Dar es Salaam, Tanzania that produces a range of pharmaceutical products, including drugs for infectious diseases
Zenufa Laboratories: Zenufa Laboratories is a pharmaceutical company based in Dar es Salaam, Tanzania that specializes in the production of generic drugs, including those used to treat infectious diseases
Africure Pharmaceuticals Limited
Keko Pharmaceutical Industries

Healthcare Policies and Reimbursement Scenarios

The Tanzania Food and Drugs Authority (TFDA) and the Ministry of Health, Community Development, Gender, Elderly, and Children oversee the regulation and reimbursement of infectious disease medicines in Tanzania. Tanzania's national health insurance programme, which is overseen by the National Health Insurance Fund, has a considerable influence on the reimbursement process for infectious disease treatments (NHIF).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

Vaccines
Drugs

By Applications (Revenue, USD Billion):

HIV/AIDS
Influenza
Hepatitis
Malaria
Tuberculosis
Others

By Disease Type (Revenue, USD Billion):

Viral Diseases
Bacterial Diseases
Fungal Diseases
Parasitic Diseases
Others

By Target Organism (Revenue, USD Billion):

Antibiotics
Antivirals
Antifungals
Anti-Parasitic
Others

By End User (Revenue, USD Billion):

Hospitals and Clinics
Ambulatory Care Centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.